薬局技師は,高コストの心臓不全薬理療法へのアクセスに与える影響
Morgan S Augustine1, Erika Nicolsen1, Alexander Reed2
1Duke University Hospital, Durham, NC, USA.
The Annals of pharmacotherapy
|February 19, 2026
まとめ
薬局の技術者は,高コストの心不全薬,サクビトリル-バルサタン,ナトリウム-グルコースコトランスポーター2阻害剤 (SGLT2i) へのアクセスを改善しました. この介入により,心不全患者の処方薬の処方率と履行率が増加しました.
科学分野:
- 心臓病学 心臓病学
- 薬理学 薬理学とは
- 医療サービス 研究 医療サービス
背景:
- 心不全のためのガイドライン指向医療療法 (GDMT) は,特にサクビトリル-バルサタンとナトリウム-グルコース共伝達体2阻害剤 (SGLT2i) は,コストのため,アクセスすることが困難です.
- 薬局技師は,心不全患者の薬へのアクセスを改善する上で重要な役割を果たすことができます.
研究 の 目的:
- 外来心不全クリニックに薬局技師を統合することで,高コストのGDMTへの患者のアクセスに与える影響を評価する.
- 具体的には,サクビトリルバルサタンとSGLT2i.へのアクセスを評価する.
主な方法:
- 遡及的,前後コホート研究デザインが採用されました.
- サクビトリルバルサータンとSGLT2iを受ける資格のある成人心不全患者は,薬局技師の実施前と後に分析されました.
- 主なアウトカムは,処方薬の適用率とサクビトリルバルサタンおよび/またはSGLT2iの充填率であり,処方薬の適用率をコントロールした.
主要な成果:
- サクビトリルバルサータンおよび/またはSGLT2iへのアクセスは,導入後の71.9%から86.5%に大幅に増加しました (OR = 2.46,P = 0.02).
- 他の心不全薬へのアクセスや入院率など,二次的なアウトカムにおいて有意な差異は認められなかった.
- 薬局の技術者は1人の患者に対して平均66.4分を費やした.
結論:
- 心不全の診療所に薬局技師を導入することで,サクビトリルバルサタンとSGLT2i.i.への患者のアクセスが著しく改善されました.
- 心不全管理における臨床結果に対する薬局技師の効果を調査するために,さらなる将来的な研究が必要である.
関連する概念動画
01:22Heart Failure VI: Adjunct Therapies
428
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
428
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.2K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
01:30Heart Failure V: Medical Management
388
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
388
01:29Cardiomyopathy V: Interprofessional Care
501
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
501
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
270
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
270
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
25
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
25